SHARPE·IQStart free
Menu
TodayResearchEarningsToolsPricingSign in
BDTX reported Third quarter ended September 30, 2026 results. The price and volatility reaction is pending.
BDTXearnings

Earnings reactions, page 4

Black Diamond Therapeutics, Inc. (BDTX) Q3 FY2026 earnings

November 10, 2026 · SharpeIQ Research Desk

Reported results

  • Research and development expenses were $7.0 million for the third quarter of 2026.
  • General and administrative expenses were $5.1 million for the third quarter of 2026.
  • Net loss for the third quarter of 2026 was $10.0 million.
  • Net loss per share - basic and diluted was $0.17 for the third quarter of 2026.
  • Cash, cash equivalents, and investments were approximately $102.0 million as of September 30, 2026.

Guidance

  • Black Diamond expects its existing cash, cash equivalents and investments to be sufficient to fund operations into the second half of 2028.

Price and volatility reaction

Source

The figures above come from the earnings release the company filed with the SEC on 2026-11-10 (8-K, Item 2.02). Read the original filing on sec.gov.

See this live in SharpeIQ

IV rank, historical IV and the single-ticker tools. The scanner and AI research are paid plans.

Open IV Rank →